Return to homepagePandemic Pact

COVID-19 monitoring, involving the measurement of C3d, antibody and the RNA copy number in the blood, with a view to elucidating whether fatal outcomes are related to an immune response or virus load, and whether the antibody response regulates or protects.

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $552,000

  • Funder

    UFM Denmark

  • Principal Investigator

    Professor Ivan Brandslund

  • Research Location

    Denmark

  • Lead Research Institution

    Lillebælt Hospital Diagnostic Centre, Institute for Regional Health Research, University of Southern Denmark, University Hospital of Southern Denmark, RLB, South Denmark Region.

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The project group will investigate whether the patient's antibody and immune system are pivotal to the seriousness of the infection and the survival of the patient. If this is the case, blood transfusions containing a lot of antibody from previous patients who have now recovered might be used to mitigate the course of the disease in new patients. Until a vaccine is available, this is one way to protect patients by passive immunisation with the appropriate antibodies.